本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Can-Fite Biopharma Ltd

2.33
+0.17007.87%
盤後2.330.00000.00%19:54 EDT
成交量:15.50萬
成交額:35.41萬
市值:499.21萬
市盈率:-0.50
高:2.37
開:2.17
低:2.16
收:2.16
52周最高:13.40
52周最低:2.16
股本:214.25萬
流通股本:214.25萬
量比:0.95
換手率:7.23%
股息:- -
股息率:- -
每股收益(TTM):-4.6460
每股收益(LYR):-1,791.0249
淨資產收益率:-211.37%
總資產收益率:-77.12%
市淨率:1.03
市盈率(LYR):0.00

資料載入中...

2026/04/01

SEC問詢函

Form CORRESP - Correspondence
2026/03/26

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/07/25

[修訂]招股説明書

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2025/07/25

SEC問詢函

Form CORRESP - Correspondence
2025/07/25

SEC問詢函

Form CORRESP - Correspondence
2025/07/23

招股説明書

Form F-1 - Registration statement for certain foreign private issuers
2025/07/17

SEC問詢函

Form CORRESP - Correspondence
2025/04/14

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/11/14

超過5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/09/06

SEC問詢函

Form CORRESP - Correspondence
2024/04/05

員工持股計劃

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/03/28

年度報告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/14

超過5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/01/03

SEC問詢函

Form CORRESP - Correspondence
2023/09/11

SEC問詢函

Form CORRESP - Correspondence
2023/04/21

員工持股計劃

S-8 - Securities to be offered to employees in employee benefit plans
2023/03/30

年度報告

20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/02/10

[修訂]招股説明書

F-1/A [Amend] - Registration statement for certain foreign private issuers
2023/02/08

SEC問詢函

CORRESP [Cover] - Correspondence
2023/01/31

招股説明書

F-1 - Registration statement for certain foreign private issuers